anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be given one dose of an identical looking sublingual placebo before performing a 10 minute speech task. Participants will then be assessed every hour for the next three hours. There will be 2 to 10 days of washout period between the randomly assigned arms of the study.
Folfirinox comprises the following: Fluorouracil 2,400 mg/m2 intravenously over 48 hours Days 1-3 and 15-17 every 4 weeks; Folinic acid 400 mg intravenously on Days 1 and 15 every 4 weeks; Oxaliplatin 85 mg/m2 intravenously on Days 1 and 15 every 4 weeks; and Irinotecan 180 mg/m2 intravenously on Days 1 and 15 every 4 weeks. Radiation will begin at the completion of cycle 2 if chemotherapy toxicity permits and will last over a period of 5 days.
The instant invention relates to the determination that constitutively nearly silent GrB locus in human breast carcinoma and osteosarcoma cells activated upon retinoblastoma protein (pRB)-induced growth arrest owing to the usage of an alternative promoter/transcription start site. Cloned novel cDNA from the locus adds 34 amino acid residues to the N-terminus of GrB zymogen. The alternate product has been designated as GrB-NIC. Tumor cells with accumulated endogenous GrB-NIC, whose mature form was identical to lymphocyte GrB but with a distinctive glycosylation pattern, undergoes post-growth-arrest apoptosis that occurs concurrently with pRB cleavage, and are capable of inducing rapid apoptosis of bystander pRB- tumor cells. Expression of GrB-NIC is also observed in malignant cells of other types as well as in normal non-immune cells upon cell differentiation, especially in differentiating and differentiated neural cells. GrB-NIC plays a physiological role in embryonic, and particularly in early neuronal development. The disclosure further provides compositions and methods utilizing this new GrB-NIC technology.
A randomized, double-blinded, clinical, placebo-controlled trial enrolling 60 male illicit AAS users with documented AAS-induced hypogonadism after a period \> 12 weeks of AAS cessation or a negative urine AAS doping test. Participants will be randomized to two study groups; 24 weeks of treatment with either tablet letrozole (femar®) initial dose of 2.5 mg each day versus tablet placebo. After an initial treatment period of four weeks, intramuscular injections with either hCG, initial dose 1500 IE twice weekly (letrozole group) or isotonic saline twice weekly (placebo group) will be added to therapy if plasma total testosterone level has not increased to target plasma level. Following 24 weeks of therapy, all participants will be observed for another 26 weeks without therapy. The study will have one trial center of recruitment: Department of Endocrinology, Rigshospitalet. Following participation in the study, all participants will be offered referral to an endocrine outpatient clinic if they still display clinical and biochemical signs of male hypogonadism.

A healthy group of 30 young lean eugonadal men, who have never used AAS, will be enrolled as control participants and undergo a screening visit and one visit including same procedures as the screening and randomization visits.
A method of reducing methane production from an animal by increasing the oxidation-reduction potential in the stomach of the animal, the method comprising orally administering to the animal a composition comprising an oxidising agent. The composition is preferably administered to the animal in a dose which provides an increase in the oxidation-reduction potential of the stomach of at least about + 100 mV for a time period of at least about 1 hour. The composition may be substantially free of iodide or a source of iodide. The oxidising agent may be an enzymatic oxidising agent system. The composition may comprise a peroxidase or catalase, a peroxidase-producing organism, or a non-biological catalyst which catalyses the decomposition of peroxide. The oxidising agent may be a source of oxygen, preferably a source of peroxide. The animal may be a ruminant, preferably a cow. Compositions for use in the method are also claimed, comprising (i) a bolus comprising an oxidising agent, excipients, and a coating or (ii) pellets comprising urea hydrogen peroxide or magnesium peroxide or a combination thereof, food components, and a coating. The compositions may comprise food components and/or be added to food prior to administration.
The present invention relates to a method for producing an isolated and purified bee venom without allergenic ingredients to produce the isolated and purified bee venom having a medicinal effect while basically preventing allergy induction by reducing or removing the allergenic ingredients in the bee venom using ultrafiltration. The method comprises: a first step for preparing the purified bee venom powder; a second step for making a bee venom solution by mixing the purified bee venom powder and distilled water; a third step for removing the allergenic ingredients contained in the bee venom solution by filtering the bee venom solution through an ultrafiltration membrane with cut-off size of 10 kDa; and a fourth step for obtaining the isolated and purified bee venom without the allergenic ingredients. At the second step, 1000-1500 ml of the distilled water is mixed with 1 g of the purified bee venom powder. At the third step, the allergenic ingredients removed through the ultrafiltration membrane are phospholipase A2 and hyaluronidase. The isolated and purified bee venom obtained at the fourth step contains at least 4% of apamin and at least 50% of melittin. [Reference numerals] (AA) START; (BB) END; (S11) Preparing purified bee venom powder; (S12) Making a bee venom solution by mixing the purified bee venom powder and distilled water; (S13) Removing the allergenic ingredients contained in the bee venom solution by filtering the bee venom solution through an ultrafiltration membrane with cut-off size of 10 kDa; (S14) Obtaining the isolated and purified bee venom without the allergenic ingredients
INTRODUCTION AND HYPOTHESIS: After vaginal pelvic organ prolapse (POP) surgery a vaginal pack and indwelling bladder catheter are inserted to reduce blood loss and bladder overdistension. The ideal timing of removal remains unclear. In this study we compared removal of vaginal pack and indwelling catheter 3 h post-surgery with removal the next day.
METHODS: This retrospective cohort study performed in the Netherlands included patients undergoing POP surgery between 1 January 2019 and 31 December 2020. Patients in whom the vaginal pack and catheter were removed the day after surgery (group A) were compared with patients in which the vaginal pack and catheter were removed 3 h post-surgery (group B). Both groups were compared regarding urinary retention and the need for re-intervention owing to active blood loss within 6 weeks postoperatively.
RESULTS: Baseline characteristics, such as age, type of operation and type of anaesthesia in group A (n = 280) and group B (n = 207) were comparable. No significant differences were found regarding complications such as urinary retention (17.2 versus 23.2%; p = 0.255). The rates of re-intervention because of active blood loss and occurrence of infection were also comparable.
CONCLUSIONS: Removal of the indwelling catheter and vaginal pack 3 h after vaginal POP surgery does not lead to more postoperative complications than removal the 1st day after surgery. Therefore, early removal is a feasible and safe alternative to the standard timing of removal the morning after surgery of women undergoing POP surgery. In the future this could help with introducing same-day discharge.
The invention relates to a formula for a mucous membrane cleaning and nursing liquid, which belongs to the field of traditional Chinese medicine. At present, with rapid development of the industry in China, the living and working environments are increasingly deteriorated; and with aggravation of air pollution, a great number of people suffer from respiratory and intestinal mucosal inflammations. The mucosal inflammations lead to lesion of internal organs, and a variety of recurring skin diseases like eczema, tinea and sores occur and cannot be cured even after long-term treatment. It is seldom reported that a botanical drug has wide-spectrum resistance to mucous membrane fungi in the world, including America; even there is such a botanical drug, the botanical drug has strong side-effects. In traditional Chinese medicine, there are a great number of botanical bactericides, but most of the botanical bactericides are prepared through mixed decoction of a plurality of plants and do not have obvious effects. According to the invention, the single plant--hawthorn fruit is used for decoction, and the obtained hawthorn fruit decoction is cooperatively used with natural plant extract xylitol and sea salt to prepare the mucous membrane nursing liquid; the mucous membrane nursing liquid is capable of searching and killing mucous membrane fungi and protecting a mucous membrane tissue structure from damage and can be widely applied to cleaning and disinfection of the mucous membrane tissue of the human body; all the components of the mucous membrane nursing liquid can be eaten, and no side-effect is produced.
The present invention provides an isolated and purified Nip, Nix and Nox proteins. There is also provided a method for inducing apoptosis in cells by transfecting a cell with a Nip, Nix and Nox proteins. Additionally, there is provided a method for inducing apoptosis in cells by creating antibodies which recognize a specific Nip, Nix and Nox proteins in a muscle or skin of a patient. A method for inducing apoptosis in cells by creating a transgene overexpressing the gene for the Nip, Nix and Nox proteins is also provided. A transgenic animal and progeny thereof is provided having an expression factor consisting essentially of a Nip, Nix and Nox proteins selected from the group consisting essentially of Seq. ID No:1 through 6.
Provided herein are methods and processes for emulsifying non-polar compounds, such as omega fatty acids. Also provided are compositions that can be prepared according to the methods and processes described herein. The compositions, for example, have a high amount of the non-polar compound, such as a large amount of omega fatty acids. The non-polar compounds are also present in very small droplets within composition. For example, the mean or median particle size of the droplets is less than about 5 µm. Further, the composition includes a low amount of surfactant, such as less than about 10-15% of the surfactant.
The study product, Umooze, contain Astragalus radix extracts and Soy extracts as the combination of 960:40 in one 500 mg tablet. Umooze is sold in the market as food. The objective of this study is to evaluate the benefit of Umooze as add- on therapy in BPH, by evaluation the improvement in symptoms of BPH assessed according to the International Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze in patients with BPH. The IPSS is a validated 7-item urinary symptom severity scale.

A randomized, two-regimen, placebo-controlled, parallel- design is used in this study in which each subject will receive Umooze or placebo. The add- on study product will be administered twice daily for 56 days. Benefit will be evaluated at baseline and subsequently on the study day 28, 42, and 56, such as IPSS index, QoL index, Qmax, PVR, prostate volume and Prostate-specific antigen(PSA).
This study explored the impact of microRNAs, specifically mmu-miR-1a-3p and mmu-miR-155-5p, on stress susceptibility and resilience in mice of different strains. Previous research had established that C57BL/6J mice were stress-susceptible, while NET-KO and SWR/J mice displayed stress resilience. These strains also exhibited variations in the serum levels of mmu-miR-1a-3p and mmu-miR-155-5p. To investigate this further, we administered antagonistic sequences (Antagomirs) targeting these microRNAs to C57/BL/6J mice and their analogs (Agomirs) to NET-KO and SWR/J mice via intracerebroventricular (i.c.v) injection. The impact of this treatment was assessed using the forced swim test. The results showed that the stress-susceptible C57/BL/6J mice could be transformed into a stress-resilient phenotype through infusion of Antagomirs. Conversely, stress-resilient mice displayed altered behavior when treated with Ago-mmu-miR-1a-3p. The study also examined the expression of mmu-miR-1a-3p in various brain regions, revealing that changes in its expression in the cerebellum (CER) were associated with the stress response. In vitro experiments with the Neuro2a cell line indicated that the Antago/Ago-miR-1a-3p and Antago/Ago-miR-155-5p treatments affected mRNAs encoding genes related to cAMP and Ca2+ signaling, diacylglycerol kinases, and phosphodiesterases. The expression changes of genes such as Dgkq, Bdnf, Ntrk2, and Pde4b in the mouse cerebellum suggested a link between cerebellar function, synaptic plasticity, and the differential stress responses observed in susceptible and resilient mice. In summary, this research highlights the role of mmu-miR-1a-3p and mmu-miR-155-5p in regulating stress susceptibility and resilience in mice and suggests a connection between these microRNAs, cerebellar function, and synaptic plasticity in the context of stress response.
Following randomisation, participants are given a schedule of group and personal meetings and details of each session. Food for the diet (red rice and lentils) will be provided for those randomised to the diet arm. The study will last 16 weeks following start of the diet/yoga programme. There will be further visits to measure outcomes at week 8 and week 16. All participants in both arms will complete the same programme of Yoga sessions, organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute.
The patient will receive an intravenous normal saline 40 ml dose just before chemotherapy begins every cycle (every 3 weeks for 6 cycles). Afterward, the same dose will be continued during the maintenance period if it is medically required or if the patient desires to do so.
A controlled release molecular iodine biocide for use in human cavities especially the vaginal, penile canal, nasal passages and rectum. Particles can be functionalized with epithelial cell binding molecules and lymphocyte-binding molecules attached to their surfaces. Half of all the particles can contain pH buffer salts that control pH to between around pH 3.5 to pH 4.5. A second half of the particles can contain Iodide and iodate salts. When pH particles and iodate/iodide particles are bound next to each other, molecular iodine is released in a controlled fashion. Molecular iodine is effective biocide. In an alternate embodiment, there can be two distinct populations of particles, one with epithelial cell binding molecules and one with lymphocyte-binding molecules. Again, half of all the particles can contain a pH buffer and half iodide and iodate salts.
The proposed study will investigate LCS-induced changes in metabolically "at-risk" young adults, under conditions that reflect typical beverage consumption. We will first identify molecular pathways potentially affected by LCS (adipose transcriptomics via global RNAseq) and then identify links between LCS-induced gene expression changes and circulating levels of key metabolic biomarkers and clinical outcomes. We will perform subcutaneous adipose biopsies before and after consumption of 12 ounces of diet soda three times daily for eight weeks. Within-subjects changes in adipose gene expression will be evaluated using RNAseq. We will then correlate transcriptomic changes with circulating levels of key inflammatory and metabolic biomarkers, to provide mechanistic insight into which pathways drive clinically-relevant LCS-induced metabolic impairments. We will measure glucose, insulin, inflammatory markers and adipose-derived hormones before and after eight weeks of LCS exposure.
The intervention will consist of initiating a chronic care management plan in the epilepsy clinic and an initial prescription from the epileptologist for escitalopram 10mg daily. Escitalopram dose adjustment will be made based on biweekly repeated screening of anxiety and depression symptoms, as well as side effects identified on biweekly telephone calls or the 6-week advanced practice provider (APP) follow up visit. Escitalopram dose may be titrated up to a maximum of 20mg daily in 5-10mg increments every 2 weeks for treatment effect, or titrated down to 5mg if needed for adverse effects. If a participant is unable to tolerate escitalopram, then venlafaxine XR 37.5mg will be substituted, to be titrated in a similar manner biweekly based on side effects and anxiety and depression symptoms (with 37.5-75mg increment dose changes and maximum dose of 225mg daily).
This is a prospective open-label observational cohort study (exploratory pilot). Investigators will include 20 patients between 18 and 65 years with chronic pain and dependence on opioids, who were referred by their physician for replacement of opioids to buprenorphine/naloxone. Exclusion criteria are contraindications for buprenorphine/naloxone and patients with psychiatric disorders requiring acute treatment. The degree of pain and withdrawal symptoms will be assessed by the Quantitative Sensory Testing (QST) measurement and the following questionnaires: Visual Analog Scale (VAS), Objective Withdrawal Scale (OWS) and Subjective Withdrawal Scale (SWS). Secondary, craving and substance use/degree of opioid dependence will be studied using the Current Opioid Misuse Measure (COMM) and Obsessive Compulsive Drug using Scale (OCDS). Psychiatric comorbidity will be assessed using the following questionnaires: Depression, Anxiety and Stress Scale (DASS), Personality Inventory for DSM-5 (PID 5-BF), The 20-item Toronto Alexithymia Scale (TAS-20), Inventory of Depressive Symptomatology (IDS), the Perseverative Thinking Questionnaire (PTQ) and Mini International Neuropsychiatric Interview (MINI). These questionnaires are part of the standard assessment at the department of psychiatry at the Radboud University Medical Centre, Nijmegen. The EuroQol five dimensions questionnaire (EQ5D) will be used to assess the quality of life. During the replacement of opioids to buprenorphine/naloxone, the buprenorphine/naloxone protocol will be used.
A 67-year-old man with type 1 diabetes, Cronkhite-Canada syndrome, and membranous nephropathy who received insulin therapy was admitted to our hospital with right hemiplegia and dysarthria. Brain magnetic resonance imaging revealed a lesion with a high diffusion-weighted imaging signal and low apparent diffusion coefficient signal in the posterior limb of the left internal capsule. He was hypoglycemic with a blood glucose level of 56 mg/dL (3.1 mmol/L). Following glucose administration, the patient's symptoms resolved within several hours. The patient experienced similar transient hypoglycemic hemiplegia at midnight, three times within 10 days. In a literature review of 170 cases of hypoglycemic hemiplegia, 26 cases of recurrent hemiplegia were investigated. Recurrent hypoglycemic hemiplegia occurs more frequently on the right side than on the left side, and most recurrences occur within approximately a week, almost exclusively at midnight and in the early morning. We speculate that hypoglycemia-associated autonomic failure may be involved in the nocturnal recurrence of episodes. In our patient, depleted endogenous insulin secretion and lipodystrophy at the injection site, may have acted as additional factors, leading to severe hypoglycemia despite the absence of apparent autonomic neuropathy. Clinically, it is important to recognize hypoglycemia as a cause of hemiplegia to avoid unnecessary intervention and to maintain an appropriate blood glucose level at midnight and early in the morning to prevent recurrent hypoglycemic hemiplegia.
Prior to the frailty screening days, information letter will be sent to the people living in the territories of action in order to present them the project. The evaluation of the level of frailty will be done in 3 steps: an inclusion visit with one of the co-investigating physicians or one of the scientific collaborators. The investigating physician will verify the eligibility criteria (inclusion and non-inclusion criteria), and will propose to the person to participate in the protocol (consent). Individuals will also have the option to participate in the screening day but refuse to sign the sheet attesting to their consent, in which case none of the data concerning them will be kept and analyzed. After consent has been obtained, individuals will be instructed to participate in the questionnaire (M0), the frailty screening visit (M0), to the analysis of medical prescriptions (M0), to a debriefing visit (M0), and a follow-up telephone visit for people detected as frail (M3, M6). For 10 volunteers per screening day, a visit to present the accelerometers will also be added (M0), as well as an assessment of physical activity assessment (+7 days).
An apparatus for medication management includes a housing for a packet of medication; a sensor coupled to the housing for sensing whether the packet has been removed or is likely to have been removed from the housing; and a transmitter for wirelessly transmitting data regarding a reading of the sensor to a remote computer. A system for medication management communicates with the apparatus for medication management is provided. The remote computer is configured to send an alert to an external device, and the alert is based on the reading of the sensor. Also, an apparatus for medication management includes a housing for medication; and a sensor for sensing a quantity of medication within the housing. The sensor includes a plurality of conductive electrodes arranged in an interleaved pattern, and provided in a substantially horizontal position. Related systems, methods, techniques and articles are also described.